ArriVent BioPharma, Inc. financial data

Symbol
AVBP on Nasdaq
Industry
Pharmaceutical Preparations
Location
18 Campus Blvd., Suite 100, Newtown Square, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.23K %
Debt-to-equity 6.68 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.7M shares
Common Stock, Shares, Outstanding 33.7M shares
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 33.6M shares +1188%
Weighted Average Number of Shares Outstanding, Diluted 33.6M shares +1188%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20.1M USD +40.7%
General and Administrative Expense 4.14M USD +70.1%
Operating Income (Loss) -24.2M USD -45%
Net Income (Loss) Attributable to Parent -20.6M USD -42.8%
Earnings Per Share, Basic -0.61 USD/shares +88.9%
Earnings Per Share, Diluted -0.61 USD/shares +88.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 283M USD
Assets, Current 292M USD
Operating Lease, Right-of-Use Asset 187K USD
Other Assets, Noncurrent 126K USD
Assets 293M USD
Accounts Payable, Current 4.65M USD
Employee-related Liabilities, Current 3.16M USD
Accrued Liabilities, Current 10.4M USD
Liabilities, Current 15.2M USD
Operating Lease, Liability, Noncurrent 56K USD
Liabilities 15.2M USD
Retained Earnings (Accumulated Deficit) -218M USD
Stockholders' Equity Attributable to Parent 277M USD
Liabilities and Equity 293M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.6M USD -10.3%
Net Cash Provided by (Used in) Financing Activities 186M USD +313%
Common Stock, Shares Authorized 200M shares
Common Stock, Shares, Issued 33.7M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 167M USD +495%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 283M USD +100%
Operating Lease, Liability 213K USD
Lessee, Operating Lease, Liability, to be Paid 229K USD
Operating Lease, Liability, Current 157K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 14K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 173K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 16K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 495M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 866M USD +301%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares